Cipla medicine price slash not to greatly affect earning

May 4, 2012 at 5:58 PM

The surprising 75% price slash by Cipla on its three cancer medicines namely Sorafenib, Gestinib and Temozolamide, will most probably not greatly affect the revenues of the pharmaceutical firm.

Labels:

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)